<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02093195</url>
  </required_header>
  <id_info>
    <org_study_id>BTCOPD-2014226</org_study_id>
    <nct_id>NCT02093195</nct_id>
  </id_info>
  <brief_title>Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients</brief_title>
  <acronym>BTCOPD</acronym>
  <official_title>Phase Ⅱ Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Present treatment for chronic obstructive pulmonary disease (COPD) has a certain role in
      reducing COPD exacerbation and hospitalization, improving the life quality, and postponing
      the lung function decline. But for some patients with severe COPD, current treatment only
      partially alleviates the symptoms and has little role in the lung function decline. In this
      randomized, multicenter study, the investigators evaluate the safety and efficacy of bosentan
      in the treatment of grade Ⅲ or Ⅳ COPD patients with pulmonary hypertension detected by
      echocardiography. The primary endpoint is the frequency of COPD exacerbation, and the
      secondary endpoint includes changes of lung function, 6-min-walk distance (6-MWD), SGRQ score
      and mMRC/CAT score.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of COPD Exacerbation</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>6-min-walk distance (6-MWD)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mMRC/CAT score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SGRQ score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bosentan,125mg,po,bid combined with inhaled Symbicort turbuhaler, 320/9μg, bid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Inhaled Symbicort turbuhaler, 320/9μg, bid.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bosentan</intervention_name>
    <arm_group_label>Bosentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort turbuhaler</intervention_name>
    <arm_group_label>Bosentan</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 75

          -  Gold Ⅲ or Ⅳ stable COPD

          -  Pulmonary hypertension detected by echocardiography

        Exclusion Criteria:

          -  Acute exacerbation of chronic obstructive pulmonary disease

          -  Untreated obstructive sleep apnea

          -  Restrictive (total lung capacity&lt;60% predicted) lung disease

          -  Portal hypertension

          -  Chronic liver disease

          -  Transaminase increased to normal line more than 3 times; total bilirubin increased 2
             times more than the upper limit of the normal value

          -  Left-sided or unrepaired congenital heart disease

          -  Patients with other serious heart diseases

          -  Patients with 1, 2, 4 and 5 categories of pulmonary hypertension

          -  Unable to complete the 6 minutes walk test

          -  Patients receiving other endothelin receptor antagonists

          -  No cooperation to complete
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengqing Li, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The department of pulmonary and critical care medicine, Xijing hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shengqing Li, MD, PhD</last_name>
    <phone>+86-29-84771132</phone>
    <email>shengqingli@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The second affiliated hospital of xi'an jiaotong university</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YUAN LIU, MD</last_name>
      <email>liuyuan@xjtu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>YUAN LIU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The department of pulmonary and critical care medicine, Xijing hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinpeng Han, MD</last_name>
      <phone>+86-29-84771135</phone>
      <email>hxp0728@163.com</email>
    </contact>
    <investigator>
      <last_name>Xinpeng Han, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaanxi Provincial People'S Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710068</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LINGBIN XU, MD</last_name>
      <email>18542705@qq.com</email>
    </contact>
    <investigator>
      <last_name>LINGBIN XU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The department of pulmonary and critical care medicine, Tangdou hospital</name>
      <address>
        <city>Xian</city>
        <state>Shaanxi</state>
        <zip>710038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yandong nan, MD</last_name>
      <email>13709205538@163.com</email>
    </contact>
    <investigator>
      <last_name>YANDONG NAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of xi'an jiaotong university</name>
      <address>
        <city>Xian</city>
        <state>Shaanxi</state>
        <zip>710064</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ting liu, MD</last_name>
      <phone>18991938962</phone>
    </contact>
    <investigator>
      <last_name>TING LIU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Shengqing Li</investigator_full_name>
    <investigator_title>Associate Chief Physician, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Treatment, COPD, bosentan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Bosentan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

